Stock Update (NYSE:MRK): Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone

[Business Wire] – Merck , known as MSD outside the United States and Canada, and NewLink Genetics Corporation , confirmed today that the third, late-stage, clinical trial of their Ebola vaccine candidate rVSV-ZEBOV-GP . . . → Read More: Stock Update (NYSE:MRK): Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone Similar Articles: Market Update (NYSE:MRK): Merck Announces Collaboration with the American Diabetes Association to Educate Adults with Diabetes About Increased Risk for Serious Diseases like Pneumococcal Pneumonia Company Update: Merck & Co Inc (NYSE:MRK) – Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer Market Update: Merck & Co Inc (NYSE:MRK) – Merck to Present at the 35th Annual Cowen Health Care Conference